

Supplementary Table 1. Clinical characteristics of recipient and donor according to recipient age and induction therapy

| Characteristic | Basiliximab induction | | | r-ATG induction | | | p-value ^a |
|-----------------------------------|-----------------------|---------------|---------|--------------------|---------------|---------|----------------------|
| | Recipient age (yr) | | p-value | Recipient age (yr) | | p-value | |
| | <60 (n = 287) | ≥60 (n = 59) | | <60 (n = 238) | ≥60 (n = 120) | | |
| Recipient characteristic | | | | | | | |
| Age (yr) | 44.3 ± 10.5 | 63.8 ± 3.6 | <0.001 | 47.0 ± 9.2 | 64.4 ± 4.0 | <0.001 | 0.33 |
| Male sex | 182 (63.4) | 42 (71.2) | 0.26 | 154 (64.7) | 81 (67.5) | 0.6 | 0.62 |
| BMI (kg/m ²) | 22.8 ± 3.5 | 23.4 ± 3.2 | 0.21 | 23.1 ± 3.5 | 23.3 ± 2.8 | 0.44 | 0.89 |
| Cause of ESRD | | | <0.001 | | | 0.001 | 0.009 |
| DM nephropathy | 68 (23.7) | 14 (23.7) | | 60 (25.2) | 48 (40.0) | | |
| HTN | 32 (11.1) | 17 (28.8) | | 17 (7.1) | 17 (14.2) | | |
| Glomerular disease | 101 (35.2) | 14 (23.7) | | 79 (33.2) | 25 (20.8) | | |
| ADPKD | 5 (1.7) | 8 (13.6) | | 9 (3.8) | 6 (5.0) | | |
| Others | 81 (28.2) | 6 (10.2) | | 73 (30.7) | 24 (20.0) | | |
| Dialysis modality prior to KT | | | 0.35 | | | 0.15 | 0.03 |
| HD | 188 (65.5) | 43 (72.9) | | 181 (76.1) | 102 (85.0) | | |
| CAPD | 38 (13.2) | 4 (6.8) | | 32 (13.4) | 10 (8.3) | | |
| Preemptive | 61 (21.3) | 12 (20.3) | | 25 (10.5) | 8 (6.7) | | |
| Comorbidities | | | | | | | |
| DM | 77 (26.8) | 20 (33.9) | 0.27 | 59 (24.8) | 53 (44.2) | <0.001 | 0.19 |
| HTN | 226 (78.7) | 49 (83.1) | 0.46 | 187 (78.6) | 106 (88.3) | 0.02 | 0.33 |
| Coronary artery disease | 22 (7.7) | 6 (10.2) | 0.6 | 21 (8.8) | 14 (11.7) | 0.39 | 0.7 |
| Cerebrovascular accident | 10 (3.5) | 2 (3.4) | >0.99 | 6 (2.5) | 12 (10.0) | 0.002 | 0.15 |
| CMV serostatus | | | 0.23 | | | 0.13 | >0.99 |
| Donor/Recipient (+/+) | 259 (91.2) | 57 (98.3) | | 224 (94.5) | 116 (99.1) | | |
| Donor/Recipient (-/+) | 9 (3.2) | 0 (0) | | 4 (1.7) | 0 (0) | | |
| Donor/Recipient (+/-) | 16 (5.6) | 1 (1.7) | | 9 (3.8) | 1 (0.9) | | |
| PRA ≥ 50% | 11 (3.9) | 0 (0) | 0.22 | 17 (7.3) | 6 (5.2) | 0.61 | 0.18 |
| Preoperative DSA | 4 (1.4) | 1 (1.8) | >0.99 | 4 (1.7) | 5 (4.3) | 0.17 | 0.67 |
| De novo DSA | 17 (6.0) | 8 (13.6) | 0.06 | 19 (8.1) | 10 (8.5) | 0.89 | 0.29 |
| HLA mismatch | | | | | | | |
| Class I ≥ 3 | 87 (30.3) | 15 (25.4) | 0.45 | 93 (39.1) | 61 (50.8) | 0.03 | 0.001 |
| Class II ≥ 2 | 56 (19.5) | 12 (20.3) | 0.88 | 41 (17.2) | 45 (37.5) | <0.001 | 0.02 |
| Follow-up duration (yr) | 5.6 (2.5–7.0) | 4.3 (1.3–7.2) | 0.08 | 3.2 (2.3–4.7) | 2.5 (1.5–3.8) | <0.001 | 0.01 |
| Donor characteristic | | | | | | | |
| Age (yr) | 44.1 ± 12.7 | 45.9 ± 15.4 | 0.417 | 47.8 ± 14.2 | 60.2 ± 15.3 | <0.001 | <0.001 |
| Male sex | 167 (58.2) | 31 (52.5) | 0.425 | 147 (61.8) | 64 (53.3) | 0.126 | 0.921 |
| BMI (kg/m ²) | 24.0 ± 3.3 | 23.5 ± 2.8 | 0.316 | 24.5 ± 3.6 | 24.2 ± 3.4 | 0.418 | 0.227 |
| Comorbidities | | | | | | | |
| Diabetes mellitus | 8 (2.8) | 4 (7.0) | 0.12 | 28 (12.0) | 25 (21.2) | 0.02 | 0.02 |
| Hypertension | 35 (12.3) | 8 (14.3) | 0.69 | 50 (21.5) | 51 (42.9) | <0.001 | <0.001 |
| Type of donor | | | | | | | |
| Living donor | 183 (67.3) | 36 (61.0) | 0.25 | 96 (40.3) | 26 (21.7) | <0.001 | <0.001 |
| SCD | 77 (26.8) | 16 (27.1) | | 76 (31.9) | 23 (19.2) | | |
| ECD | 17 (5.9) | 7 (11.9) | | 66 (27.7) | 71 (59.2) | | |
| Terminal creatinine level (mg/dL) | 0.93 ± 0.51 | 0.95 ± 0.52 | 0.81 | 1.59 ± 1.24 | 1.66 ± 1.31 | 0.64 | <0.001 |

Data are expressed as mean ± standard deviation, number (%), or median (interquartile range).

ADPKD, autosomal dominant polycystic kidney disease; BMI, body mass index; CAPD, continuous ambulatory peritoneal dialysis; CMV, cytomegalovirus; DM, diabetes mellitus; DSA, donor-specific antibody; ECD, extended criteria donor.; ESRD, end-stage renal disease; HD, hemodialysis; HLA, human leukocyte antigen; HTN, hypertension; KT, kidney transplantation; PRA, panel reactive antibody; r-ATG, rabbit anti-thymocyte globulin; SCD, standard criteria donor.

^aComparison of basiliximab and r-ATG induction in recipient aged ≥60 years.